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Summary A disturbed energy balance has been demonstrated in lung cancer patients. Both an enhanced resting energy expenditure (REE)
and a decreased energy intake contribute to weight loss. Enhanced systemic levels of inflammatory mediators were found to be related to the
enhanced REE in lung cancer. The aim of the present study was to investigate energy metabolism and systemic levels of inflammatory
mediators in small-cell lung carcinoma (SCLC) patients before and after treatment with chemotherapy. Hypermetabolism and an enhanced
inflammatory response have already been demonstrated in SCLC by our group before. Twelve newly diagnosed SCLC patients were
consecutively included in the study. REE was measured by indirect calorimetry and body composition was determined by bioelectrical
impedance (BIA) before and 1 month after treatment. To assess the inflammatory state the acute-phase proteins, C-reactive protein (CRP)
and lipopolysaccharide-binding protein (LBP), both soluble tumour necrosis factor (TNF) receptors, (sTNF-R)-55 and sTNF-R75, and soluble
intercellular adhesion molecule (slCAM)-1 were measured in plasma before and 1 month aftertreatment. CRP was assessed byturbidemetry,
whereas the other inflammatory parameters were measured by enzyme-linked immunosorbent assay (ELISA). A significant reduction in REE
was found irrespective of therapeutic outcome, whereas body weight and body composition remained stable. The acute-phase proteins CRP
and LBP were reduced significantly after treatment with chemotherapy, whereas both sTNF receptors and sICAM-1 remained enhanced. No
correlation, however, existed between the decrease in REE and the decrease in the acute-phase proteins. In conclusion, chemotherapeutic
treatment attenuates the tumour-related metabolic derangements and acute-phase response.
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Weight loss is a frequently occurring problem in lung cancer
patients. Severe weight loss (2 10% weight loss) has been found in
30% of patients with newly detected lung cancer (Staal et al,
1994). Both an increased resting energy expenditure (REE) and a
decreased energy intake contribute to weight loss in lung cancer
patients (Russell et al, 1984; Hansell et al, 1986; Fredrix et al,
1991; Staal et al, 1994). Apart from body composition, the local-
ization ofthe tumour in the central airways and enhanced systemic
levels of inflammatory mediators were found to be determining
factors of an increased REE in lung cancer patients (Staal et al,
1994; 1995). The involvement ofinflammatory mediators in meta-
bolic derangements has been demonstrated in experimental animal
studies as well as in oncological patients with different tumour
types (Fong et al, 1989; Denz et al, 1993; Falconer et al, 1994;
Staal et al, 1995).
In addition to general tumour characteristics, histology has to be
considered as a factor related to energy metabolism in lung cancer
patients. Lung cancer can be divided into small-cell lung carci-
noma (SCLC) and non-small-cell lung carcinoma (NSCLC)
(Robbins et al, 1984). Approximately 20% of the patients with
lung cancer have SCLC. SCLC has different characteristics from
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NSCLC, ofwhich the presence ofneurosecretory granules, a more
aggressive behaviourand agood response to chemotherapy are the
most important (Carney, 1992).
An enhanced REE adjusted for fat-free mass (FFM) was
demonstrated in SCLC patients compared with NSCLC patients in
a previous study by our group (Staal et al, 1997). Limited data
have been published about the effects of treatment on REE in
SCLC (Russell etal, 1984; Jebb etal, 1994). No follow-up data are
available at present about the effects of treatment on REE in rela-
tion to levels ofinflammatory mediators in SCLC.
The aim of the present study was to assess energy metabolism
and systemic levels of inflammatory mediators in patients with
SCLC before and after standard treatment with chemotherapy. The
acute-phase response was assessed by C-reactive protein (CRP)
andlipopolysaccharide-binding protein (LBP), whereas inflamma-
tion was evaluated by measurement of both soluble TNF recep-
tors, sTNF receptor (sTNF-R)-55 and sTNF-R75 and soluble
intercellular adhesion molecule (sICAM)-l, a member of the
immunoglobulin supergene family.
SUBJECTS AND METHODS
Patients
Twelve newly diagnosed SCLC patients were consecutively
included into the study. All patients had histologically documented
tumours and had not yet received treatment before the first
measurements. The exclusion criteria for the study were: previous
treatment with chemotherapy or radiotherapy; treatment with high
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doses of corticosteroids; severe endocrine abnormalities (insulin-
dependent diabetes mellitus, hyper/hypothyroidism); and body
temperature exceeding 37.7°C. The two-stage classification system
was used for SCLC (Mountain, 1986; Patel et al, 1993). Staging
procedures consisted of physical and neurological examination,
bronchoscopy to collect materials for histological examination,
echoscopy ofthe abdomen, computerized tomography (CT) scan of
the thorax and abdomen, CT scan and magnetic resonance imaging
(MRI) of the brain and a bone scan. Patients were treated with
five courses of chemotherapy, consisting of cyclophosphamide
1000 mg m-2 on day 1, doxorubicin 45 mg m-2 on day 1 and etopo-
side 100 mg on days 1, 3 and 5 with a dose reduction of 25% if
necessary. Approximately 1 month after the end of treatment,
patients were restaged. Tumour responses were defined according
to accepted criteria (Mountain, 1986; Patel et al, 1993).
The study was approved by the medical ethics committee ofthe
university hospital of Maastricht. Written informed consent was
obtained from all patients.
Resting energy expenditure
REE was measured by indirect calorimetry using a ventilated hood
system (Oxycon P, Mijnhardt, Bunnik, The Netherlands). The flow
through thecanopy waskeptconstantduring measurements and was
adjusted to the weight ofthe patient, ranging from 35 to 45 1 min-'.
The equipment was calibrated at the start ofevery experiment. The
accuracy of the procedure was checked monthly by burning
methanol (respiratory quotient of0.667 aftercomplete combustion).
After an overnight fast in the hospital and while atcomplete rest, the
pretreatment REE measurement was made on the metabolic ward
over a 20-min period between 07.00 h and 09.00 h in quiet circum-
stances. The post-treatment measurement was performed in a
similar mannerbuton an outpatient basis. A previous study (Fredrix
et al, 1990a) showed that variations because of limited physical
activities, including short travelling time from home to the hospital,
did not significantly influence the measurement ofREE.
Body composition
Body height was measured with the subject standing barefoot and
determined to the nearest 0.5 cm. Body weight was measured
using a beam scale (SECA, Germany), with the subject standing
without shoes in underwear, to the nearest 0.1 kg. Fat-free mass
(FFM) was assessed using the single-frequency bioelectrical
impedance (BI) analysis (RJL-Systems, BIA-101, Detroit, MI,
USA). Resistance was measured with the subject in the supine
position on the right side, as described previously (Lukaski et al,
1985). FFM was measured in the early morning after REE
measurement to avoid the influence of exercise or eating
(Deurenberg et al, 1988; Schols et al, 1990). The BI method is a
non-invasive, safe, rapid and reproducible measurement of body
composition (Chumlea and Baumgartner, 1989; Zarowitz and
Pilla, 1989). In a previous study, a good correlation was estab-
lished between height2/resistance and total body water (TBW), as
assessed by deuterium dilution in elderly cancer patients (Fredrix
et al, 1990b). The patient-specific regression equation used was
based on that study. Adjustment of REE for the metabolically
active tissue mass or FFM is indicated for a correct interpretation
of the variations in REE (Lukaski et al, 1985; Deurenberg et al,
1988; Schols et al, 1990).
Fat mass (FM) was calculated as body weight minus FFM.
Dietary intake
Dietary intake during the period before admission and after treat-
ment was estimated using the diet history method (Cameron and
van Staveren, 1988). All interviews were performed by the same
trained dietician within the first week after admission to the
hospital and after the chemotherapeutic regimens. Dietary intake
was calculated using the nutrient database derived from the Dutch
food composition tables (NEVO, 1990).
Plasma samples
Blood was obtained by venepuncture from patients before
breakfast on the same day of the REE measurement. Blood
was collected in evacuated blood collection tubes (Sherwood
Medical, St. Louis, MO, USA) containing 50 IU heparin (Leo
Pharmaceutical Products, Weesp, The Netherlands). Plasma was
separated from blood cells by centrifugation at 1000 g for 5 min
within 1 h of collection. Plasma samples were stored at -70'C
until analysis.
Measurement of inflammatory mediators
To assess inflammation, a series of inflammatory mediators were
determined in plasma. Both soluble TNF receptors, sICAM-1 and
the acute-phase proteins CRP and LBP were measured using sand-
wich ELISA as described previously (Leeuwenberg et al, 1992,
1994; Froon et al, 1995). CRP was determined as described below.
In short, for measurement of sTNF-R55 and sTNF-R75, MAbs
MR1-1 and MR2-2 were used for coating respectively. Specific
biotin-labelled polyclonal rabbit anti-human sTNF-R55 IgGs were
used as detector reagents. The standards used were recombinant
human sTNF-R55 and sTNF-R75. The detection limit of both
assays was 100 pg ml-'. For sICAM-1 ELISA, MAb HM.2 was
used for coating and recombinant human (rh) sICAM-1 was used
as a standard. Biotinylated MAb HM.1 was used fordetection. The
detection limit ofthe assay was 400 pg ml-'. Polyclonal rabbit anti
rhLBP IgG was used as coating for the LBP ELISA and biotin-
labelled polyclonal rabbit anti rh LBP IgG was used for detection
of LBP. The standard used was recombinant LBP. Washing and
dilution were performed in buffer containing 40 mm magnesium
chloride forpreventing disturbance by LPS ofLBP recovery in the
ELISA. The detection limit of the assay was 200 pg ml-'.
Immunoassay plates (Nunc-Immuno Plate Maxisorp, Roskilde,
Denmark) were used for the ELISA assays. Biotinylated
samples were detected with streptavidin-peroxidase conjugate
(Dako, Glostrup, Denmark). TMB (3,3',5,5'-tetramethylbenzidine,
Kirkegaard & Perry Laboratory, Gaithersburg, MD, USA) was
used as a substrate. Photospectometry (450 nm) was performed
using a micro ELISA autoreader. CRP was measured by
turbidimetry. The detection limit ofthe assay was 5 gg ml-'.
Biochemical parameters
To exclude hyper/hypothyroidism, thyroid-stimulating hormone
(TSH) was assessed with an immunoradiometric assay. Cortisol
was determined to evaluate adrenal function and possible ectopic
cortisol production that could be observed in SCLC (Shepherd et
al, 1992; Collichio et al, 1994). Cortisol was measured with a
radioimmunoassay. Plasma creatinine was used as a renal function
parameter and detected by the modificated Jasse reaction
(Dimension, Dupont, France) (Larsen, 1972).
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Table 1 Description of the study population
Physical characteristics
M/F 10:2
Age (years) 62 ± 10
Weight (kg) 63.7 ± 9.5
Height (cm) 168.1 ± 6.4
FFM (kg) 48.2 ± 5.8
PIBW (%) 97.7± 11.1
Weight loss (kg) 4.0 ± 4.5
Tumour stage (n)
Limited disease 4
Extensive disease 8
Data are expressed as means ± s.d. FFM, fat-free mass; PIBW, percentage
ideal body weight; n = number of patients.
Statistics
Weight loss was calculated by the difference between reported
preillness stable weight minus actual weight. REE was expressed
in absolute terms and adjusted for FFM according to Ravussin
(Ravussin and Bogardus, 1989). Statistical analyses were
performed using the paired Student's t-test when appropriate. The
Wilcoxon test was used for analysis of non-parametric data. As
impaired renal clearance leads to increased sTNF-receptor concen-
trations (Brockhaus et al, 1992; Froon et al, 1994), the plasma
concentrations of sTNF-R55 and sTNF-R75 were analysed
together with serum creatinine. Therefore, an analysis of covari-
ance was performed using plasma creatinine as covariable and
considering sTNF-R55 and sTNF-R75 as factors in the statistical
model. Frequency data were compared using the chi-square test.
Results are presented as means ± standard deviation (s.d). P-values
<0.05 were defined as statistically significant. The statistical
calculations were performed by the SPSS/PC + 4.0 package
(SPSS/PC +, 1990).
RESULTS
The pretreatment characteristics ofthe SCLC patients are summa-
rized in Table 1. Ten men and two women were included in the
study (age 62 ± 10 years). Mean weight loss for the whole group
was 4.0 ± 4.5 kg. Five patients were current smokers, whereas
seven patients stopped smoking during the last 6 months. Mean
levels of TSH were 1.4 ± 0.8 mU 1-' and mean levels of cortisol
were 588 ± 130 nmol 1.-' Both TSH and cortisol levels were within
the normal range (TSH normal range 0.-3.5 mU 1-l, cortisol
normal range 200-700 nmol 1-1). Normal renal function according
to plasma creatinine was found in the SCLC patients before (83 ±
22 jmol 1-1) and after treatment (76 ± 14 ,umol 1-1). All patients
showed tumourreduction aftertreatment and could be classified as
partial or complete remission. Four patients showed a complete
remission, whereas eightpatients showed apartial remission ofthe
tumour after treatment with chemotherapy.
Data on body composition and energy balance of the SCLC
patients before and after treatment are given in Table 2. All
patients were hypermetabolic before treatment. Body weight and
body composition of the patients remained stable. REE expressed
in absolute value (1628 ± 219 kcal day-' vs 1475 ± 130 kcal day-',
P = 0.01) and REE adjusted for FFM (1807 ± 226 kcal day-' vs
1629 ± 160 kcal day-', P < 0.005) decreased significantly after
treatment. Energy intake was measured in a subgroup (n = 6)
Table 2 Comparison of body composition and energy balance before and
after treatment in SCLC patients
Before After P-value
(n= 12) (n= 12)
Weight (kg) 63.7 ± 9.5 65.5 ± 10.0
FFM (kg) 48.2 ± 5.8 49.1 ± 6.0
FM (kg) 15.5 7.5 16.4 ± 7.3
REE (kcal day-') 1628 219 1475 ± 130
Adjusted REE (kcal dar') 1807 ± 226 1629 ± 160
*P= 0.01; **P< 0.005. Data are expressed as means ± s.d. FFM, fat-free
mass; FM, fat mass; REE, resting energy expenditure.
Table 3 Systemic levels of inflammatory mediators in SCLC before and
after treatment with chemotherapy
Before After P-value
(n=12) (n=12)
sTNF-R55 (ng ml-') 1.6 ± 0.6 1.5 ± 0.5
sTNF-R75 (ng ml-' 2.0 ± 1.0 2.0 ± 0.8
siCAM - 1 (ng ml-') 78.0 ± 40.4 76.8 ± 27.8
CRP (gg ml-') 33 41 15 20
LBP (gg ml-') 23.0 ± 10.9 16.3 ± 8.5
*P< 0.05. Data are expressed as means ± s.d. sTNF-R55, soluble TNF-
receptor 55; sICAM-1, soluble intercellular adhesion molecule 1; CRP,
C-reactive protein; LBP, LPS-binding protein.
before and after treatment and did not change significantly
(2156 ± 444 vs 2154 ± 391 kcal day-').
The systemic levels ofinflammatory mediators are summarized
in Table 3. Both acute-phase proteins CRP (33 ± 41 jig ml-l
vs 15 ± 20 jig ml-, P < 0.05) and LBP (23.0 ± 10.9 jig ml' vs
16.3 ± 8.5gg ml-, P <0.05) decreased significantly aftertreatment
with chemotherapy, whereas sTNF-R55 (1.6 + 0.6 ng ml-' vs 1.5
± 0.5 ng ml-'), sTNF-R75 (2.0 ± 1.0 ng ml' vs 2.0 ± 0.8 ng ml-')
and sICAM-l (78.0 ± 40.4 ng ml-' vs 76.8 ± 27.8 ng ml-') did not
change significantly after treatment with chemotherapy. Both
sTNF-receptors and sICAM-1 levels were enhancedcomparedwith
healthy control subjects as described in a previous study (Staal-van
den Brekel et al, 1995). No correlation could be demonstrated
between the decrease in REE or adjusted REE and the decrease of
the acute-phase proteins. The individual values for REE, adjusted
REE, CRP and LBP from all patients are shown in Figure 1.
DISCUSSION
The present study describes the metabolic and inflammatory char-
acteristics of 12 patients with newly detected SCLC before and
after treatment with chemotherapy. A significant reduction in
REE, both expressed in absolute terms and adjusted for FFM, was
found, whereas body weight and body composition remained
stable. Both acute-phase proteins CRP and LBP reduced signifi-
cantly after treatment with chemotherapy, whereas both sTNF-
receptors and sICAM-1 remained elevated. No correlation,
however, existed between the decrease in REE or adjusted REE
and the decrease in the acute-phase proteins.
Hypermetabolism frequently occurs in lung cancer, as has been
described previously both in NSCLC and in SCLC (Russell et al,
1984; Hansell et al, 1986; Fredrix et al, 1991; Staal et al, 1994).
Body composition is the most important determinant of REE.
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Figure 1 The individual values of the metabolic parameters and acute-phase proteins are shown for all patients. To, time before the start ofchemotherapeutic
treatment; Tl, time 1 month after the end ofchemotherapeutic treatment. REE, resting energy expenditure; CRP, C-reactive protein; LBP, LPS-binding protein
After treatment withchemotherapy, nosignificantchanges in FFM
and FM occuffed in SCLC patients in the present study. The
observed decrease in REE could not therefore be attributed to
changes in body composition. The decrease in REE was not
related to a decrease in energy intake. The extent ofthe coffection
of the energy balance expressed in kcal day-' suggests that the
follow-up period is possibly too short to observe changes in body
composition. The short survival time in SCLC limits the possible
duration of afollow-upperiod (O'Connell et al, 1986; Osterlind et
al, 1986). The findings of stable energy intake during treatment
with chemotherapy in SCLC confinn previously reported data
(Ovesen et al, 1992). Theimproved treatment of nausea, vomiting
andpain, all known to diminishappetite and food intake, could be
related to this stabilization ofenergy intake.
Tumour stage, tumour size, pulmonary function and smoking
behaviour do not influence the metabolic parameters in lung
cancerpatients as has been demonstratedpreviously (Fredrix etal,
1991; Staal et al, 1994; 1995). No significant changes in
pulmonary function and smoking behaviour could be detected
before and afterchemotherapeutic treatment(data not shown).
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Based on the relationship between metabolic derangements and
the inflammatory response in several groups of cancer patients
(Denz et al, 1993; Falconer et al, 1994; Staal et al, 1995), changes
in levels ofinflammatory mediators were considered to explain the
decrease in resting energy expenditure. In the present study, a
significant reduction in the levels ofboth acute-phase proteins CRP
and LBP was found aftertreatment withchemotherapy, whereas the
levels of both sTNF receptors and sICAM-1 remained elevated.
These data are the first reported changes in inflammatory state after
chemotherapy in SCLC. The drop in acute-phase response could
implicate a decrease in the hepatic metabolic rate. The liver forms
part ofthe FFM and is considered as a high energy-requiring organ
just like the skeletal muscles and brain (Nelson et al, 1992). The
oxygen consumption ofthe human liver is estimated to amount to+
65 ml min-' and covers 25% of total REE in healthy people,
whereas skeletal muscles and brain cover 25% and 20%, respec-
tively, of total REE (Nelson et al, 1992). Although an increased
oxygen consumption in hepatocytes is described in sarcoma-
bearing rats compared with pair-fed controls, no experimental data
are at present available on hepatic metabolism in relation to tumour
management (Roh et al, 1985). Further studies on compartmenta-
lization ofchanges in metabolic rate in metabolically active tissues
are necessary to fully understand apossible contribution ofthe liver
or other tissues to these metabolic derangements.
Although the levels of acute-phase proteins reduced signifi-
cantly after treatment with chemotherapy, levels of both sTNF
receptors remained elevated. Enhanced levels ofboth sTNFrecep-
tors have been described previously in patients with various types
ofcancer (Aderka et al, 1991; Digel et al, 1992; Denz et al, 1993;
Langkopf et al, 1994). However, the effects oftreatment on levels
of both sTNF receptors in cancer patients have not yet beenf
reported. An impaired renal clearance could notbe attributed tothe
persistence ofenhanced levels ofboth sTNF receptors (Brockhaus
et al, 1992; Froon et al, 1994). No disturbed renal function was
detected in any of the patients and, in addition, plasma creatinine
was considered as a covariable in the analysis of covariance for
both sTNF receptors. Another explanation for the enhanced levels
could be that both TNF receptors are shed by SCLC cells after cell
death. Enhanced expression of both TNF receptors has been
demonstrated on carcinoma cells of different origins (Gatanaga et
al, 1993; Biberstein et al, 1995). There is evidence that tumour
cells have a greater tendency than non-malignant cells to produce
and shed soluble forms oftheircell-surface proteins (Black, 1980).
In contrast, cell death could induce systemic inflammation
resulting in enhanced levels ofboth sTNF receptors. Furthermore,
at least in patients with partial remission and possibly in patients
with complete remission, tumour cells could still be present.
In addition to levels of both soluble TNF receptors, the soluble
isoform of ICAM-1 was measured. ICAM-1 is a member of the
immunoglobulin supergene family and plays an important role in
inflammatory and immune responses (Rothlein et al, 1988). The
possible role of circulating adhesion molecules is not yet fully
elucidated. By competing with the membrane-bound receptors for
their ligands, the release of adhesion molecules may induce a
decrease in the potential adhesiveness of leucocytes (Shingu et al,
1994). Otherwise, soluble adhesion molecules can act as co-stimu-
latory factors: sICAM-1 has been demonstrated to deliverchemoki-
netic signals to lymphocytes and to enhance cytotoxic production
and T-cell proliferative responses stimulated by alloantigen in
mixed lymphocyte cultures (McCabe et al, 1993). Based on the
correlation between high sICAM-1 levels and reduced survival
rates in patients with malignant melanoma (Harning et al, 1991), it
has also been suggested that sICAM-1 may represent an escape
mechanism for tumours from the cytotoxicity mediated by
immunoeffector cells (Becker et al, 1991). It is of note that in
cultured renal tumour cells an inverse relationship was found
between expression and release ofICAM-l (Santarosa et al, 1995).
In the same study, enhanced levels ofsICAM-1 were demonstrated
in renal cancer patients with metastatic disease compared with
tumour-free patients 4 weeks after nephrectomy. However, half of
the tumour-free patients still had enhanced levels of sICAM-1
(Santarosa et al, 1995). Our data confirm the persistence of
enhanced sICAM-1 levels despite chemotherapeutic intervention in
SCLC patients. Increased sICAM-1 levels have been reported to
correlate with disease activity (Tsujisaki et al, 1991) in a wide range
oforgan-specific diseases, and circulating levels of sICAM-1 were
indicators of disease progression in various malignant tumours
(Shijubo et al, 1992; Gruss et al, 1993; Christiansen et al, 1994;
Wolff et al, 1995). The role of the soluble adhesion molecules,
however, needs to be elucidated in furtherhuman studies.
In conclusion, chemotherapeutic treatment attenuates the
tumour-related metabolic derangements and acute-phase response.
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